Impact of medication adherence on risk of ischemic stroke, major bleeding and deep vein thrombosis in atrial fibrillation patients using novel oral anticoagulants

References

• January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014;130:2071-104
   PubMed Web of Science ®Google Scholar
• Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5
   PubMed Web of Science ®Google Scholar
• Prevention CoDCa. Atrial Fibrillation Fact Sheet 2015. Available at: http://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_atrial_fibrillation.htm [Last accessed 17 April 2016]
   Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8
   PubMed Web of Science ®Google Scholar
• Noel P, Gregoire F, Capon A, et al. Atrial fibrillation as a risk factor for deep venous thrombosis and pulmonary emboli in stroke patients. Stroke 1991;22:760-2
   PubMed Web of Science ®Google Scholar
• Enga KF, Rye-Holmboe I, Hald E, et al. Atrial fibrillation and future risk of venous thromboembolism: the Tromsø study. J Thromb Haemost 2015;13:10-16
   PubMed Web of Science ®Google Scholar
• Cove CL, Hylek EM. An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes. J Am Heart Assoc 2013;2:e000136
   PubMed Web of Science ®Google Scholar
• Akin M, Schäfer A, Akin I, et al. Use of new oral anticoagulants in the treatment of venous thromboembolism and thrombotic prophylaxis. Cardiovasc Haematol Disord Drug Targ 2015;15:92-6
   PubMedGoogle Scholar
• Seeger J, Bykov K, Bartels D, et al. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost 2015;114:1277-89
   PubMed Web of Science ®Google Scholar
• Yao X, Abraham NS, Alexander GC, et al. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc 2016;5:e003074
   PubMed Web of Science ®Google Scholar
• Shiga T, Naganuma M, Nagao T, et al. Persistence of non-vitamin K antagonist oral anticoagulant use in Japanese patients with atrial fibrillation: a single-center observational study. J Arrhythmia 2015;31:339-44
   PubMed Web of Science ®Google Scholar
• Zalesak M, Siu K, Francis K, et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circulation Cardiovasc Qual Outcomes 2013;6:567-74
   PubMed Web of Science ®Google Scholar
• Bailey JE, Wan JY, Tang J, et al. Antihypertensive medication adherence, ambulatory visits, and risk of stroke and death. J Gen Intern Med 2010;25:495-503
   PubMed Web of Science ®Google Scholar
• Herttua K, Tabak AG, Martikainen P, et al. Adherence to antihypertensive therapy prior to the first presentation of stroke in hypertensive adults: population-based study. Eur Heart J 2013;34:2933-9
   PubMed Web of Science ®Google Scholar
• Burke JP, Sander S, Shah H, et al. Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors. Curr Med Res Opin 2010;26:1023-30
   PubMed Web of Science ®Google Scholar
• Böhm M, Schumacher H, Laufs U, et al. Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease. Am Heart J 2013;166:306-314.e7
   PubMed Web of Science ®Google Scholar
• Ezekowitz MD, Wallentin L, Connolly SJ, et al. Dabigatran and warfarin in vitamin K antagonist–naive and –experienced cohorts with atrial fibrillation. Circulation 2010;122:2246-53
   PubMed Web of Science ®Google Scholar
• Austin PC, Stuart EA. The performance of inverse probability of treatment weighting and full matching on the propensity score in the presence of model misspecification when estimating the effect of treatment on survival outcomes. Stat Methods Med Res 2017;26:1654-1670
   PubMed Web of Science ®Google Scholar
• Zhu W-G, Xiong Q-M, Hong K. Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation. Texas Heart Institute J 2015;42:6-15
   PubMed Web of Science ®Google Scholar
• Shore S, Carey EP, Turakhia MP, et al. Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. Am Heart J 2014;167:810-17
   PubMed Web of Science ®Google Scholar
• Gorst-Rasmussen A, Skjoth F, Larsen TB, et al. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. J Thromb Haemost 2015;13:495-504
   PubMed Web of Science ®Google Scholar
• McHorney CA, Crivera C, Laliberté F, et al. Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measure. Curr Med Res Opin 2015;31:2167-73
   PubMed Web of Science ®Google Scholar
• Brown JD, Shewale AR, Talbert JC. Adherence to rivaroxaban, dabigatran, and apixaban for stroke prevention in incident, treatment-naïve nonvalvular atrial fibrillation. J Manag Care Specialty Pharmacy 2016;22:1319-29
   PubMedGoogle Scholar
• Beyer-Westendorf J, Förster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 2014;124:955-62
   PubMed Web of Science ®Google Scholar
• Weeda ER, White CM, Peacock WF, et al. Rates of major bleeding with rivaroxaban in real-world studies of nonvalvular atrial fibrillation patients: a meta-analysis. Curr Med Res Opin 2016;32:1117-20
   PubMed Web of Science ®Google Scholar
• Mercaldi CJ, Siu K, Sander SD, et al. Long-term costs of ischemic stroke and major bleeding events among Medicare patients with nonvalvular atrial fibrillation. Cardiol Res Pract 2012;2012:Article ID 645469, 13 pages doi:10.1155/2012/645469
   PubMedGoogle Scholar
• Fitch K, Broulette J, Kwong WJ. The economic burden of ischemic stroke and major hemorrhage in Medicare beneficiaries with nonvalvular atrial fibrillation: a retrospective claims analysis. Am Health Drug Benefits 2014;7:200
   PubMedGoogle Scholar
• Cardiac Medications. Dallas, TX: American Heart Association, 2016. Available at: http://www.heart.org/HEARTORG/Conditions/Heart-Attack/PreventionTreatmentofHeartAttack/Cardiac-Medications_UCM_303937_Article.jsp#.V4vRnPkrLIV [Last accessed 17 July 2016]
   Google Scholar